摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

benzyl 7-(2-(2-aminopyrimidin-5-yl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate | 1099640-12-6

中文名称
——
中文别名
——
英文名称
benzyl 7-(2-(2-aminopyrimidin-5-yl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate
英文别名
Benzyl 7-[2-(2-aminopyrimidin-5-yl)phenyl]-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate;benzyl 7-[2-(2-aminopyrimidin-5-yl)phenyl]-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate
benzyl 7-(2-(2-aminopyrimidin-5-yl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate化学式
CAS
1099640-12-6
化学式
C23H20N8O2
mdl
——
分子量
440.464
InChiKey
FORKFTWEKATNQN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    33
  • 可旋转键数:
    6
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.13
  • 拓扑面积:
    130
  • 氢给体数:
    2
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    2-氨基嘧啶-5-硼酸benzyl 7-(2-bromophenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate 在 bis-triphenylphosphine-palladium(II) chloride potassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.75h, 以68%的产率得到benzyl 7-(2-(2-aminopyrimidin-5-yl)phenyl)-5-methyl-4,7-dihydrotetrazolo[1,5-a]pyrimidine-6-carboxylate
    参考文献:
    名称:
    SUBSTITUTED HETEROCYCLIC COMPOUNDS
    摘要:
    本发明涉及新颖的杂环化合物及其在治疗各种疾病状态中的应用,包括心血管疾病和糖尿病。在特定实施例中,化合物的结构由公式(I)给出:其中Q1、Q2、R2、R3、R4、R5和R6如本文所述。该发明还涉及制备这些化合物的方法,以及含有这些化合物的药物组合物。
    公开号:
    US20090012103A1
点击查看最新优质反应信息

文献信息

  • US8716319B2
    申请人:——
    公开号:US8716319B2
    公开(公告)日:2014-05-06
  • US9045428B2
    申请人:——
    公开号:US9045428B2
    公开(公告)日:2015-06-02
  • [EN] OPTIONALLY CONDENSED DIHYDROPYRIDINE, DIHYDROPYRIMIDINE AND DIHYDROPYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE DIHYDROPYRIDINE, DIHYDROPYRIMIDINE ET DIHYDROPYRANE FACULTATIVEMENT CONDENSÉS AGISSANT COMME BLOQUEURS DES CANAUX CALCIQUES TARDIFS
    申请人:CV THERAPEUTICS INC
    公开号:WO2009006580A1
    公开(公告)日:2009-01-08
    The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
  • [EN] OPTIONALLY CONDENSED DIHYDRO PYRIDINE, DIHYDROPYRIMIDINE AND DIHYDRO PYRANE DERIVATIVES ACTING AS LATE SODIUM CHANNEL BLOCKERS<br/>[FR] DÉRIVÉS DE DIHYDROPYRIDINE, DE DIHYDROPYRIMIDINE ET DE DIHYDROPYRANE FACULTATIVEMENT CONDENSÉS, JOUANT LE RÔLE DE BLOQUEURS TARDIFS DES CANAUX SODIQUES
    申请人:CV THERAPEUTICS INC
    公开号:WO2010002483A1
    公开(公告)日:2010-01-07
    The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Ql, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    申请人:Abelman Matthew
    公开号:US20090012103A1
    公开(公告)日:2009-01-08
    The present invention relates to novel heterocyclic compounds and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula (I): wherein Q1, Q2, R2, R3, R4, R5, and R6 are as described herein. The invention also relates to methods for the preparation of the compounds, and to pharmaceutical compositions containing such compounds.
    本发明涉及新颖的杂环化合物及其在治疗各种疾病状态中的应用,包括心血管疾病和糖尿病。在特定实施例中,化合物的结构由公式(I)给出:其中Q1、Q2、R2、R3、R4、R5和R6如本文所述。该发明还涉及制备这些化合物的方法,以及含有这些化合物的药物组合物。
查看更多